Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 93 of 1,261
  1. US 12091463

    Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)

    Orionis Biosciences, Inc Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  2. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  3. US 12091386

    D-amphetamine compounds, compositions, and processes for making and using the same

    Zevra Therapeutics, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  4. US 12091410

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  5. US 12091411

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  6. US 12091426

    Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

    NURIX THERAPEUTICS, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  7. US 12090227

    Method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion

    STANDARD FOODS (CHINA) CO., LTD Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  8. US 12091661

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  9. US 12090193

    Glucagon-like peptide 1 receptor agonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  10. US 12091388

    Solid state forms of Reproxalap

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  11. US 12090209

    Twin base linkers for virus inactivation

    Northwestern University Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  12. US 12091407

    Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof

    VTV THERAPEUTICS LLC Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  13. US 12091675

    Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

    Takeda Pharmaceutical Company Limited Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  14. US 12090175

    Compositions and methods for tissue repair with extracellular matrices

    The Regents of the University of California Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  15. US 12090142

    Combination therapy for the treatment of cancer

    The Board of Regents of the University of Texas System Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  16. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  17. US 12091440

    IL2 and peptide-MHC complex fusion proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  18. US 12091486

    Block copolymer and micelle compositions and methods of use thereof

    The Board of Regents of the University of Texas System Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  19. US 12089575

    Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  20. US 12090206

    Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels

    The Regents of the University of California Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  21. US 12090201

    Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  22. US 12091387

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  23. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted
  24. US 12090183

    Methods of treating solid or lymphatic tumors by combination therapy

    CG ONCOLOGY, INC. Β· Granted Sep 17, 2024 Β· Expires Sep 12, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.